Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...
Gilead Sciences waves an active trigger finger for acquisitions. After loading up on cancer drugs through a number of deals in recent years, the biopharma powerhouse is looking for new targets, Bloomberg reported. And Gilead's interest in blood-cancer drugs sparked some speculation about a couple of likely buyout prospects.
The FDA is wrapping up business before the end of the year and making a flurry of approvals. The agency OK'd three new drugs Friday, with all of the green-lighted therapies sanctioned for combating relatively rare ailments and securing orphan drug status.
Ariad's plan to launch its maiden commercialization effort took hard shape today as the FDA announced that it had approved ponatinib for two types of leukemia. Tapped as a likely blockbuster by a number of analysts, Ariad gained regulatory approval for the targeted treatment a full three months ahead of its regulatory deadline.
Five months after Merck's woeful application for ridaforolimus was shown the door at the FDA, the Europeans repeated the regulatory coup de grace on the other side of the Atlantic.
The FDA has granted the company an accelerated review of the targeted cancer treatment for patients who have failed previous treatment for chronic myeloid leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia. The speedy review comes with action date of March 27.
With its lead drug ponatinib on track to a likely approval in the U.S. and Europe, Ariad Pharmaceuticals ($ARIA) moved center stage at ESMO 2012 over the weekend with an early-stage cancer drug that produced some impressive results among a small population of non-small cell lung cancer patients.
Investigators behind the big T-DM1 breast cancer program took the lid off the last big data box from its pivotal study this morning, revealing that the armed antibody delivered a 32% reduction in the risk of death among patients in the pivotal Phase III study when compared to the standard-of-care arm.
Ariad Pharmaceuticals picked up an accelerated review for its promising leukemia drug ponatinib from the European Union's drug regulator as the Cambridge, MA-based biotech steams ahead with plans to commercialize the blockbuster hopeful over the next year.
Ariad Pharmaceuticals ($ARIA) has taken another big step toward its first big regulatory approval, shaving weeks off its schedule to file an application for ponatinib in the U.S. as it races to the market with a new leukemia treatment.